Pharmaceuticals Industry Report – 2025 Transforming Molecules into Medicines

Highlights of the report

The global pharmaceutical industry is entering a pivotal period marked by rapid scientific advancement, evolving healthcare demands, and substantial market transformation. Innovation remains the core engine of growth, particularly in biologics, biosimilars, oncology, immunology, and metabolic disorders.

AI in Insurance – 2025 Personalized Policies Powered by AI

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Pharmaceutical R&D is undergoing a significant shift as companies adopt platform-based technologies, leverage AI and machine learning for discovery and clinical trial optimization, and integrate biomarkers to support precision medicine. These advancements aim to improve R&D productivity and reduce timelines; however, development costs remain extremely high, and late-stage failures continue to limit commercial success.

The global pharmaceutical industry is one of the most critical pillars of healthcare, driven by innovation, demographic change, and unmet medical needs. Valued at trillions of dollars, it continues to expand as populations age, the prevalence of chronic diseases rises, and emerging markets gain access to better healthcare infrastructure.

The pharmaceutical industry presents high-growth opportunities in biologics, GLP-1 therapies, AI enabled R&D, and advanced therapies, but these are counterbalanced by structural risks including patent expiries, pricing constraints, and supply-chain vulnerabilities.

Table of Contents
• Executive Summary
• CrispIdea Research
• CrispIdea Outlook
• Global Pharmaceuticals Market Overview
• R&D Evolution & Innovation
• Key Therapeutic Areas
• Biopharma & Advanced Therapies
• Manufacturing & Supply Chain
• Competitive Landscape
• Challenges
• Company Reports
―Eli Lilly and Company
―Novartis AG
―AbbVie
―Gilead Sciences
―Merck & Co
―Pfizer
―Twist Bioscience
―Teva Pharmaceuticals
―Dr. Reddy’s Laboratories
―AstraZeneca
―Roche Holding AG
―Novo Nordisk
• Bibliography

This report was produced by a member company of the Crispidea. This report is for the use of intended recipients only and may not be reproduced (in whole or in part) or delivered or transmitted to any other person without our prior written consent. By accepting this report, the recipient agrees to be bound by the terms and limitations set out herein.

https://www.crispidea.com/report-category/sector-research-reports-industry/

Report details

Pharmaceuticals Industry Report – 2025 Transforming Molecules into Medicines

  • Pages
  • 412
  • Format
  • PDF
  • Language
  • English
  • Released
  • December 18, 2025
  • Last Updated
  • December 18, 2025

Price

$2,000.00

Company Reports

Salesforce

Salesforce Inc Q1FY27 (CRM) – $25bn ASR supports attractive valuation

Salesforce Inc Q1FY27 – Salesforce’s current valuation provides an attractive entry point as the stock has corrected significantly despite continued improvement in earnings, profitability, and AI adoption.
$248 Purchase
Analog Devices

Analog Devices,INC. (ADI) (Q2FY26) – Why we are raising ADI to $440?

Analog Devices,INC. (ADI) (Q2FY26) – The company’s products are built for average lifecycles of 15 to 20 years, making them highly stable.
$248 Purchase
Hyundai

Hyundai Motor Company Q4FY25 (005380.KS) (Q1FY26) – Operational leverage mismatch vs. Secular growth engines

Hyundai Motor Company Q1FY26 – While global automotive industry demand dropped 7.2% in Q1, Hyundai limited its global wholesale decline to just 2.5%, capturing clear market share.
$216 Purchase

Commvault Systems (CVLT) (Q4FY26) – Subscription strength supports future growth outlook

Commvault systems continues to demonstrate strong execution in its transition toward a subscription led business model, supported by accelerating recurring revenue and healthy customer expansion.
$224 Purchase
Siemens

Siemens AG Q2FY26 (SEIGY) – Two-speed execution cycle restricts near-term valuation rerating

Siemens AG Q2FY26 – Smart Infrastructure has successfully decoupled from standard non-residential construction cycles, transforming into a secular growth engine driven by data center and semiconductor facility capital expenditure.
$248 Purchase
Cisco Systems

Cisco Systems Inc Q3FY26 (CSCO) – The old networking guard or the new AI giant?

Cisco Systems Inc Q3FY26 – The company is a highly attractive stock for dividend investors, having raised its payout for fourteen consecutive years.
$256 Purchase

Sector Reports

“ANTIQ” 1H26: THE COLLECTIVE SEMICONDUCTOR STOCK PERFORMANCE

Semiconductors remain vital to modern electronics, powering devices like smartphones, tablets, and PCs. While the industry has recovered from pandemic disruptions, it now faces geopolitical tensions, regulatory shifts, and supply chain diversification efforts.
$1450 Purchase
tokenisation

Tokenization: Turning Real-World Value into Digital Opportunity

Tokenization is reshaping how financial assets are issued, settled, and stored. The technology is proven, regulations are advancing, and major asset managers are already moving capital onto blockchain-based systems.
$230 Purchase
Humanoid

Humanoid Vol.1: The Dawn of the Embodied AI Revolution

Asia-Pacific (APAC) region is dominant in the global humanoid robot market, accounting for 36.52% of worldwide market share in 2026. With more than one-third of the global market, Asia-Pacific has established itself as the leading region in humanoid robotics adoption, development, and production.
$300 Purchase

The Magnificent 7: Q1 2026 Performance

The Magnificent 7: Q1 2026 Performance: The consolidated Q1 2026 chart reveals a period of synchronized valuation compression and de-risking across mega-cap technology. For the first time in several quarters, the overarching theme was one of universal negative absolute returns, as every single member of the Magnificent Seven finished the window in the red.
$1200 Purchase

Green Fintech 2026 Unlocking Value Across the Green Fintech Revolution

Green Fintech 2026 ecosystem has officially entered a high-velocity growth cycle, transitioning from an early-stage venture experiment into mission-critical financial infrastructure. Driven by active global regulatory mandates
$230 Purchase
SpaceX IPO

SpaceX IPO analysis: The rocket that reached everything

The proposed $1.75 trillion SpaceX IPO represents a fundamental disruption to the traditional architecture of public equity markets, aerospace defense primes, and global technology ecosystems, triggering cascading effects across telecommunications infrastructure, orbital logistics and artificial intelligence capital deployment that extend far beyond traditional industrial boundaries.
$299 Purchase